Impact Of JCA And Project Orbis On The European Revenue Potential Of An Oncology Product

A conversation with Claudio Valenti

A primary industry concern regarding the Joint Clinical Assessment (JCA) and Project Orbis has been the risk of faster price erosion from International Reference Pricing (IRP). However, a new financial analysis suggests this fear may be overstated. Research presented by Claudio Valenti indicates that while some accelerated price erosion occurs initially, the effect is minimal by the fifth year post-launch. More importantly, this is more than offset by a faster uptake in volume. The net result is a positive financial impact, with a projected base-case revenue increase of 11% over five years for a new oncology product utilizing these pathways.

Get the details on this revenue analysis by reading the full article.